JANX
Janux Therapeutics, Inc.
NASDAQ · Healthcare · Biotechnology · US
$16.74
+1.39%Year over year
Reported trailing growth
- Revenue
- +5367.0%
- EBITDA
- +16.2%
- EBIT
- +0.9%
- EPS
- +8.3%
- Free cash flow
- +30.9%
- Operating cash flow
- +31.0%
Forward estimates
Based on analyst estimates
- Revenue
- -39.9%
- EBITDA
- -55.1%
- EPS
- -52.9%
Three-year CAGR
- Revenue
- +5.1%
- EBITDA
- -66.7%
- EBIT
- -59.5%
- Net income
- -64.7%
- EPS
- -43.0%
- Free cash flow
- -88.5%
Reported trailing growth, forward expectations and three-year compound growth rates · Data as of Jun 1, 2026